Dopa for Parkinsonism.

The L-dopa response in vascular parkinsonism.

OBJECTIVE To determine whether a positive L-dopa response in vascular parkinsonism (VP) is correlated with the presence of nigrostriatal pathology due to either vascular damage or neuronal cell loss. METHODS Seventeen patients with pathologically confirmed VP were selected from the pathological collection of the Queen Square Brain Bank for Neurological Disorders, and their L-dopa response dur...

DNAJC12 and dopa-responsive nonprogressive parkinsonism.

Biallelic DNAJC12 mutations were described in children with hyperphenylalaninemia, neurodevelopmental delay, and dystonia. We identified DNAJC12 homozygous null variants (c.187A>T;p.K63* and c.79-2A>G;p.V27Wfs*14) in two kindreds with early-onset parkinsonism. Both probands had mild intellectual disability, mild nonprogressive, motor symptoms, sustained benefit from small dose of levodopa, and ...

L-dopa responsive parkinsonism secondary to a subdural haematoma.

We report a 53-year-old woman who developed a reversible, L-dopa responsive parkinsonian syndrome in the context of a recurrent right-sided subdural haematoma. The syndrome occurred during a prolonged stay in hospital and resolved completely during the following year. Parkinsonism is a rare but recognised complication of subdural haematoma.

Reversal of the glabellar reflex in Parkinsonism by L-dopa.

L-dopa and carbidopa (sinemet) in the management of parkinsonism.

Parkinsonism is a degenerative disease. A weakening in the responsiveness to dopamine replacement therapy affects many patients: thus 45% fail to maintain their initial improvement after 2 years' and 50% after 3 years' medication. However, by reducing the peripheral and systemic side actions of dopamine through the selective introduction of sinemet, a decarboxylase inhibitor+ L-dopa combination...